alendronate has been researched along with Carotid Stenosis in 4 studies
alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.
Carotid Stenosis: Narrowing or stricture of any part of the CAROTID ARTERIES, most often due to atherosclerotic plaque formation. Ulcerations may form in atherosclerotic plaques and induce THROMBUS formation. Platelet or cholesterol emboli may arise from stenotic carotid lesions and induce a TRANSIENT ISCHEMIC ATTACK; CEREBROVASCULAR ACCIDENT; or temporary blindness (AMAUROSIS FUGAX). (From Adams et al., Principles of Neurology, 6th ed, pp 822-3)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Particulated dosage forms of bisphosphonates, such as polymeric nanoparticles and liposomes, deplete circulating monocytes and attenuate inflammation." | 5.34 | Additive-free albumin nanoparticles of alendronate for attenuating inflammation through monocyte inhibition. ( Golomb, G; Koroukhov, N; Markovsky, E, 2007) |
| " Intravenous (IV) and intraperitoneal (IP) liposomal alendronate (LA) treatments have been shown to deplete circulating monocytes and peritoneal macrophages resulting in the inhibition of restenosis and endometriosis (EM), respectively." | 3.76 | Route of administration-dependent anti-inflammatory effect of liposomal alendronate. ( Afergan, E; Ben-David, M; Epstein, H; Golomb, G; Gutman, D; Haber, E; Koroukhov, N; Schachter, M, 2010) |
| "Particulated dosage forms of bisphosphonates, such as polymeric nanoparticles and liposomes, deplete circulating monocytes and attenuate inflammation." | 1.34 | Additive-free albumin nanoparticles of alendronate for attenuating inflammation through monocyte inhibition. ( Golomb, G; Koroukhov, N; Markovsky, E, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cohen-Sela, E | 1 |
| Chorny, M | 1 |
| Koroukhov, N | 3 |
| Danenberg, HD | 1 |
| Golomb, G | 3 |
| Haber, E | 1 |
| Afergan, E | 1 |
| Epstein, H | 1 |
| Gutman, D | 1 |
| Ben-David, M | 1 |
| Schachter, M | 1 |
| Shimshi, M | 1 |
| Abe, E | 1 |
| Fisher, EA | 1 |
| Zaidi, M | 1 |
| Fallon, JT | 1 |
| Markovsky, E | 1 |
4 other studies available for alendronate and Carotid Stenosis
| Article | Year |
|---|---|
A new double emulsion solvent diffusion technique for encapsulating hydrophilic molecules in PLGA nanoparticles.
Topics: Acetates; Alendronate; Animals; Biological Availability; Bone Density Conservation Agents; Carotid S | 2009 |
Route of administration-dependent anti-inflammatory effect of liposomal alendronate.
Topics: Alendronate; Animals; Anti-Inflammatory Agents; Carotid Stenosis; Chemistry, Pharmaceutical; Disease | 2010 |
Bisphosphonates induce inflammation and rupture of atherosclerotic plaques in apolipoprotein-E null mice.
Topics: Alendronate; Animals; Aorta; Apolipoproteins E; Arteriosclerosis; Carotid Stenosis; Diphosphonates; | 2005 |
Additive-free albumin nanoparticles of alendronate for attenuating inflammation through monocyte inhibition.
Topics: Albumins; Alendronate; Animals; Carotid Stenosis; Cell Line; Cross-Linking Reagents; Diffusion; Drug | 2007 |